What is the equity of Gilead Sciences this year?
Gilead Sciences has equity of 22.83 B USD this year.
In 2024, Gilead Sciences's equity was 22.83 B USD, a 7.5% increase from the 21.24 B USD equity in the previous year.
In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.
Gilead Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Gilead Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Gilead Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Gilead Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Gilead Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Gilead Sciences has equity of 22.83 B USD this year.
The equity of Gilead Sciences has increased/decreased by 7.5% increased compared to the previous year.
A high equity is advantageous for investors of Gilead Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Gilead Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Gilead Sciences can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Gilead Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Gilead Sciences include profits, dividend payments, capital increases, and acquisitions.
The equity of Gilead Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Gilead Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 4.48 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.
The current dividend yield of Gilead Sciences is 4.48 %.
Gilead Sciences pays a quarterly dividend. This is distributed in the months of October, January, April, July.
Gilead Sciences paid dividends every year for the past 15 years.
For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.94 %.
Gilead Sciences is assigned to the 'Health' sector.
To receive the latest dividend of Gilead Sciences from 6/27/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 6/14/2024.
The last dividend was paid out on 6/27/2024.
In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.
The dividends of Gilead Sciences are distributed in USD.
The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.